Bajaj Healthcare earnings calls.

Bajaj Healthcare delivered a solid Q1 FY27 with revenue of ₹165.66 croreCurrent reported value: ₹165.66 crore. No comparable prior figure is available in the source record. (+11.3Current reported value: 11.3. No comparable prior figure is available in the source record.% YoY) driven by 27% growth in domestic API and margin expansion to 17.8Current reported value: 17.8. No comparable prior figure is available in the source record.% EBITDA (+70bps YoY). Management guided to 10-15% revenue growthCurrent reported value: 10-15% revenue growth. No comparable prior figure is available in the source record. for FY27 and targets ₹900-1,000 crore revenue in 3-4 years. Key near-term catalysts include a 250kg peptide facility commissioning in Q4 FY27 (potential ₹200-300 crore peak revenue at 18-20% margins) and SEC recommendation for Syntocinomic tablets (₹10-12 crore FY27 opportunity). The export segment remains depressed at ~18% of revenue due to geopolitical headwinds, but six EU/UK DMF approvals position the company for FY28-29 commercialization. Management committed to ₹40-50 crore annual capex and flagged working capital efficiency (receivables at 131 days, targeting 110-120). Two loss-making Tarapur plants remain unsold. Risk: FY27 growth guidance of 10-15% appears modest given the high base and assumes stabilization in export revenues, which may prove optimistic if geopolitical conditions persist.